Author:
Rodriguez-Otero Paula,San-Miguel Jesús F
Reference9 articles.
1. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial;Lonial;Lancet Haematol,2022
2. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study;Lonial;Lancet Oncol,2020
3. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med,2021
4. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up;Martin;J Clin Oncol,2022
5. Teclistamab in relapsed or refractory multiple myeloma;Moreau;N Engl J Med,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献